Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Lung Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 152 articles:
HTML format
Text format



Single Articles


    March 2020
  1. GAINOR JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, et al
    Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression >/=50.
    Ann Oncol. 2020;31:404-411.
    PubMed     Text format     Abstract available


    February 2020
  2. MANSFIELD AS, Kazarnowicz A, Karaseva N, Sanchez A, et al
    Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
    Ann Oncol. 2020;31:310-317.
    PubMed     Text format     Abstract available


  3. MAZIERES J, Cropet C, Montane L, Barlesi F, et al
    Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations.
    Ann Oncol. 2020;31:289-294.
    PubMed     Text format     Abstract available


  4. PROS E, Saigi M, Alameda D, Gomez-Mariano G, et al
    Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
    Ann Oncol. 2020;31:274-282.
    PubMed     Text format     Abstract available


  5. PARK K, Vansteenkiste J, Lee KH, Pentheroudakis G, et al
    Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
    Ann Oncol. 2020;31:191-201.
    PubMed     Text format     Abstract available


    January 2020
  6. HAZELL SZ, Fu W, Hu C, Voong KR, et al
    Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life.
    Ann Oncol. 2020;31:96-102.
    PubMed     Text format     Abstract available


  7. DE RUYSSCHER D, Faivre-Finn C, Nackaerts K, Jordan K, et al
    Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer.
    Ann Oncol. 2020;31:41-49.
    PubMed     Text format     Abstract available


    December 2019
  8. YOSHIOKA H, Shimokawa M, Seto T, Morita S, et al
    Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell
    Ann Oncol. 2019;30:1978-1984.
    PubMed     Text format     Abstract available


  9. KIM C, Liu SV
    First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward.
    Ann Oncol. 2019;30:1852-1855.
    PubMed     Text format    


    November 2019
  10. MOUNTZIOS G, Remon J, Novello S, Blais N, et al
    Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >/=1% by the USA Food and Drug Administration.
    Ann Oncol. 2019;30:1686-1688.
    PubMed     Text format    


    October 2019
  11. KIM C, Liu SV
    First-line EGFR TKI therapy in Non-Small Cell Lung Cancer: Looking back before leaping forward.
    Ann Oncol. 2019 Oct 15. pii: 5587761. doi: 10.1093.
    PubMed     Text format    


  12. DE VRIES R, Muller M, van der Noort V, Theelen WSME, et al
    Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
    Ann Oncol. 2019;30:1660-1666.
    PubMed     Text format     Abstract available


  13. AGUILAR EJ, Ricciuti B, Gainor JF, Kehl KL, et al
    Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
    Ann Oncol. 2019;30:1653-1659.
    PubMed     Text format     Abstract available


    September 2019
  14. YOSHIOKA H, Shimokawa M, Seto T, Morita S, et al
    Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell
    Ann Oncol. 2019 Sep 25. pii: 5573754. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. DE VRIES R, Muller M, van der Noort V, Theelen WSME, et al
    Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
    Ann Oncol. 2019 Sep 17. pii: 5567488. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. MOUNTZIOS G, Remon J, Novello S, Blais N, et al
    Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of >/= 1% by the U.S. Food and Drug Administration.
    Ann Oncol. 2019 Sep 3. pii: 5559466. doi: 10.1093.
    PubMed     Text format    


  17. KUDO Y, Haymaker C, Zhang J, Reuben A, et al
    Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
    Ann Oncol. 2019;30:1521-1530.
    PubMed     Text format     Abstract available


    August 2019
  18. WEISS JM, Csoszi T, Maglakelidze M, Hoyer RJ, et al
    Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial.
    Ann Oncol. 2019 Aug 27. pii: 5555303. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. AGUILAR EJ, Ricciuti B, Gainor JF, Kehl KL, et al
    Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.
    Ann Oncol. 2019 Aug 21. pii: 5552557. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2019
  20. KUDO Y, Haymaker C, Zhang J, Reuben A, et al
    Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer.
    Ann Oncol. 2019 Jul 8. pii: 5529670. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. CHAMPIAT S, Besse B, Marabelle A
    Hyperprogression during immunotherapy: do we really want to know?
    Ann Oncol. 2019;30:1028-1031.
    PubMed     Text format    


  22. TAMMINGA M, Groen HJM
    Circulating tumor cells are prognostic in SCLC, but still lack clinical application.
    Ann Oncol. 2019;30:1031-1033.
    PubMed     Text format    


  23. PASTORINO U, Silva M, Sestini S, Sabia F, et al
    Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy.
    Ann Oncol. 2019;30:1162-1169.
    PubMed     Text format     Abstract available


  24. KELLY RJ, Shepherd FA, Krivoshik A, Jie F, et al
    A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
    Ann Oncol. 2019;30:1127-1133.
    PubMed     Text format     Abstract available


  25. SHAW AT, Riely GJ, Bang YJ, Kim DW, et al
    Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Ann Oncol. 2019;30:1121-1126.
    PubMed     Text format     Abstract available


  26. TAY RY, Fernandez-Gutierrez F, Foy V, Burns K, et al
    Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    Ann Oncol. 2019;30:1114-1120.
    PubMed     Text format     Abstract available


  27. KIM CG, Kim KH, Pyo KH, Xin CF, et al
    Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Ann Oncol. 2019;30:1104-1113.
    PubMed     Text format     Abstract available


  28. ROTA M, Pizzato M, La Vecchia C, Boffetta P, et al
    Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis.
    Ann Oncol. 2019;30:1040-1043.
    PubMed     Text format    


    June 2019
  29. FRUH M, Peters S
    EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer.
    Ann Oncol. 2019 Jun 14. pii: 5518918. doi: 10.1093.
    PubMed     Text format    


  30. PASTORINO U, Silva M, Sestini S, Sabia F, et al
    Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy.
    Ann Oncol. 2019 Jun 5. pii: 5511622. doi: 10.1093.
    PubMed     Text format    


    May 2019
  31. MAZIERES J, Drilon A, Lusque A, Mhanna L, et al
    Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
    Ann Oncol. 2019 May 24. pii: 5498206. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. HASTINGS K, Yu H, Wei W, Sanchez-Vega F, et al
    EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.
    Ann Oncol. 2019 May 14. pii: 5488949. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. KELLY RJ, Shepherd FA, Krivoshik A, Jie F, et al
    A Phase 3, Randomized, Open-label Study of ASP8273 Versus Erlotinib or Gefitinib in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer.
    Ann Oncol. 2019 May 9. pii: 5487410. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. ROTA M, Pizzato M, La Vecchia C, Boffetta P, et al
    Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis.
    Ann Oncol. 2019 May 2. pii: 5482568. doi: 10.1093.
    PubMed     Text format    


  35. PLANCHARD D, Popat S, Kerr K, Novello S, et al
    Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".
    Ann Oncol. 2019;30:863-870.
    PubMed     Text format    


  36. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Correction to: "Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer".
    Ann Oncol. 2019;30:858.
    PubMed     Text format    


  37. BLUMENTHAL GM, Gong Y, Kehl K, Mishra-Kalyani P, et al
    Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.
    Ann Oncol. 2019;30:830-838.
    PubMed     Text format     Abstract available


    April 2019
  38. TAY RY, Fernandez-Gutierrez F, Foy V, Burns K, et al
    Prognostic value of circulating tumour cells in limited-stage small cell lung cancer: analysis of the concurrent ONce-daily versus twice-daily RadioTherapy (CONVERT) randomised controlled trial.
    Ann Oncol. 2019 Apr 24. pii: 5479461. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. SHAW AT, Riely GJ, Bang YJ, Kim DW, et al
    Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Ann Oncol. 2019 Apr 13. pii: 5448502. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. KIM CG, Kim KH, Pyo KH, Xin CF, et al
    Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Ann Oncol. 2019 Apr 12. pii: 5448854. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. PASTORINO U, Silva M, Sestini S, Sabia F, et al
    Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial.
    Ann Oncol. 2019 Apr 1. pii: 5425325. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. WIESWEG M, Mairinger F, Reis H, Goetz M, et al
    Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer.
    Ann Oncol. 2019;30:655-657.
    PubMed     Text format    


    March 2019
  43. PETERS S, Reck M, Smit EF, Mok T, et al
    How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.
    Ann Oncol. 2019 Mar 26. pii: 5420157. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. HANNIGAN B, Ye W, Mehrotra M, Lam V, et al
    Liquid Biopsy Assay for Lung Carcinoma Using Centrifuged Supernatants from Fine Needle Aspiration Specimens.
    Ann Oncol. 2019 Mar 18. pii: 5384494. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. EKMAN S
    HER2: defining a Neu target in non-small-cell lung cancer.
    Ann Oncol. 2019;30:353-355.
    PubMed     Text format    


    February 2019
  46. BLUMENTHAL GM, Gong Y, Kehl K, Mishra-Kalyani P, et al
    Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in clinical trials of patients with non-small cell lung cancer.
    Ann Oncol. 2019 Feb 22. pii: 5362014. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. WIESWEG M, Mairinger F, Reis H, Goetz M, et al
    Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small cell lung cancer.
    Ann Oncol. 2019 Feb 11. pii: 5315508. doi: 10.1093.
    PubMed     Text format    


  48. MORABITO A
    Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!
    Ann Oncol. 2019 Feb 2. pii: 5306111. doi: 10.1093.
    PubMed     Text format    


  49. AMARAL SR, Casal Moura M, Carvalho J, Chaves A, et al
    6PPrognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  50. WANG M, Ma X
    26PTexture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  51. XIE Y
    35PEnhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  52. BRONTE G, Puccetti M, Crino L, Bravaccini S, et al
    Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression.
    Ann Oncol. 2019;30:339-340.
    PubMed     Text format    


  53. BOFFETTA P, Righi L, Ciocan C, Pelucchi C, et al
    Reply to letters to the editor by Brentisci et al. and Consonni and Mensi.
    Ann Oncol. 2019;30:341.
    PubMed     Text format    


  54. CONSONNI D, Mensi C
    Comment on the paper 'Boffetta et al. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. Ann Oncol 2018; 29(2): 484-489'.
    Ann Oncol. 2019;30:340-341.
    PubMed     Text format    


  55. WU YL, Planchard D, Lu S, Sun H, et al
    Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
    Ann Oncol. 2019;30:171-210.
    PubMed     Text format     Abstract available


  56. MORABITO A
    Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!
    Ann Oncol. 2019;30:165-167.
    PubMed     Text format    


  57. PETERS S, Dafni U, Boyer M, De Ruysscher D, et al
    Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
    Ann Oncol. 2019;30:161-165.
    PubMed     Text format    


    January 2019
  58. ZUO H, Ueland PM, Midttun O, Tell GS, et al
    Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3).
    Ann Oncol. 2019 Jan 30. pii: 5304407. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. PLANCHARD D, Popat S, Kerr K, Novello S, et al
    Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jan 30. pii: 5304567. doi: 10.1093.
    PubMed     Text format    


  60. PETERS S, Dafni U, Boyer M, De Ruysscher D, et al
    Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
    Ann Oncol. 2019 Jan 8. pii: 5280724. doi: 10.1093.
    PubMed     Text format    


  61. DE LIMA LOPES G, Aguiar P Jr
    Reply to the letter to the editor 'Response to the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors' by Ogale.
    Ann Oncol. 2019;30:149-150.
    PubMed     Text format    


    December 2018
  62. WANG Y, Jiang T, Qin Z, Jiang J, et al
    HER2 exon 20 insertions in Non-Small Cell Lung Cancer are Sensitive to the Irreversible Pan-HER Receptor Tyrosine Kinase Inhibitor Pyrotinib.
    Ann Oncol. 2018 Dec 31. pii: 5267836. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. WU YL, Planchard D, Lu S, Sun H, et al
    Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
    Ann Oncol. 2018 Dec 28. pii: 5265324. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  64. WAN Y, Liu B, Lei H, Zhang B, et al
    Nanoscale Extracellular Vesicle-Derived DNA is Superior to Circulating Cell Free DNA for Mutation Detection in Early-Stage Non-Small Cell Lung Cancer.
    Ann Oncol. 2018 Oct 18. pii: 5136413. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. PLANCHARD D, Popat S, Kerr K, Novello S, et al
    Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29.
    PubMed     Text format    


    September 2018
  66. GADGEEL S, Peters S, Mok T, Shaw AT, et al
    Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
    Ann Oncol. 2018 Sep 12. pii: 5095692. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. TANIGUCHI Y, Takeda M, Tamiya A, Kasai T, et al
    Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small cell lung cancer.
    Ann Oncol. 2018 Sep 10. pii: 5094491. doi: 10.1093.
    PubMed     Text format    


    August 2018
  68. KRON A, Alidousty C, Scheffler M, Merkelbach-Bruse S, et al
    Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
    Ann Oncol. 2018 Aug 23. pii: 5079835. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. COSTA DB
    TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.
    Ann Oncol. 2018 Aug 23. pii: 5110095. doi: 10.1093.
    PubMed     Text format    


  70. THOMAS M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, et al
    Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study.
    Ann Oncol. 2018 Aug 20. pii: 5076437. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  71. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Text format     Abstract available


  72. SORIA JC, Ho SN, Varella-Garcia M, Iafrate AJ, et al
    Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small cell lung cancer.
    Ann Oncol. 2018 Jul 13. pii: 5053587. doi: 10.1093.
    PubMed     Text format     Abstract available


  73. COTTRELL TR, Thompson ED, Forde PM, Stein JE, et al
    Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC).
    Ann Oncol. 2018 Jul 6. pii: 5049993. doi: 10.1093.
    PubMed     Text format     Abstract available


  74. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ann Oncol. 2018 Jul 3. pii: 5048419. doi: 10.1093.
    PubMed     Text format    


    June 2018
  75. BONOMI PD, Gandara D, Hirsch FR, Kerr KM, et al
    Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
    Ann Oncol. 2018 Jun 14. pii: 5037893. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  76. GERBER DE, Horn L, Boyer M, Sanborn R, et al
    Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
    Ann Oncol. 2018 May 14. pii: 4996069. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  77. PINATO DJ, Kythreotou A, Mauri FA, Suardi E, et al
    Functional immune characterization of HIV-associated non-small cell lung cancer.
    Ann Oncol. 2018 Apr 20. pii: 4979448. doi: 10.1093.
    PubMed     Text format    


  78. NOVELLO S, Mazieres J, Oh IJ, de Castro J, et al
    Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
    Ann Oncol. 2018 Apr 14. pii: 4970555. doi: 10.1093.
    PubMed     Text format     Abstract available


  79. WANG H, Agulnik J, Kasymjanova G, Wang A, et al
    Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.
    Ann Oncol. 2018 Apr 12. pii: 4969231. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. MULLER DC, Hodge AM, Fanidi A, Albanes D, et al
    No association between circulating concentrations of vitamin D and risk of lung cancer: An analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3).
    Ann Oncol. 2018 Apr 2. pii: 4958387. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. DACIC S
    Time is up for PD-L1 testing standardization in lung cancer.
    Ann Oncol. 2018;29:791-792.
    PubMed     Text format    


    March 2018
  82. DEROSA L, Hellmann MD, Spaziano M, Halpenny D, et al
    Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer.
    Ann Oncol. 2018 Mar 30. pii: 4956695. doi: 10.1093.
    PubMed     Text format     Abstract available


  83. TAO MH, Chen S, Freudenheim JL, Cauley JA, et al
    Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
    Ann Oncol. 2018 Mar 29. pii: 4956655. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  84. MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
    Ann Oncol. 2018 Feb 26. pii: 4909805. doi: 10.1093.
    PubMed     Text format    


  85. VOKES EE, Ready N, Felip E, Horn L, et al
    Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
    Ann Oncol. 2018 Feb 2. pii: 4835443. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  86. ADAM J, Le Stang N, Rouquette I, Cazes A, et al
    Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.
    Ann Oncol. 2018 Jan 16. pii: 4812668. doi: 10.1093.
    PubMed     Text format     Abstract available


  87. LI YS, Jiang BY, Yang JJ, Zhang XC, et al
    Unique Genetic Profiles from Cerebrospinal Fluid Cell-free DNA in Leptomeningeal Metastases of EGFR-mutant Non-Small Cell Lung Cancer: A New Medium of Liquid Biopsy.
    Ann Oncol. 2018 Jan 15. pii: 4810473. doi: 10.1093.
    PubMed     Text format     Abstract available


  88. LAVOLE A, Guihot A, Veyri M, Lambotte O, et al
    PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?
    Ann Oncol. 2018 Jan 15. pii: 4810471. doi: 10.1093.
    PubMed     Text format    


  89. GUIBERT N, Hu Y, Feeney N, Kuang Y, et al
    Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
    Ann Oncol. 2018 Jan 9. pii: 4794870. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. GHORANI E, Rosenthal R, McGranahan N, Reading JL, et al
    Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
    Ann Oncol. 2018;29:271-279.
    PubMed     Text format     Abstract available


  91. ILIE M, Szafer-Glusman E, Hofman V, Chamorey E, et al
    Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ann Oncol. 2018;29:193-199.
    PubMed     Text format     Abstract available


  92. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ann Oncol. 2018;29.
    PubMed     Text format     Abstract available


    December 2017
  93. KORDBACHEH T, Honeychurch J, Blackhall F, Faivre-Finn C, et al
    Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.
    Ann Oncol. 2017 Dec 22. pii: 4772556. doi: 10.1093.
    PubMed     Text format     Abstract available


  94. GUIHOT A, Marcelin AG, Massiani MA, Samri A, et al
    Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
    Ann Oncol. 2017 Dec 1. pii: 4677259. doi: 10.1093.
    PubMed     Text format    


  95. BI N, Liang J, Wang L
    Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.
    Ann Oncol. 2017;28:3101-3103.
    PubMed     Text format    


    November 2017
  96. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    Nivolumab in non-small cell lung cancer with EGFR mutation.
    Ann Oncol. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format    


  97. EK L, Gezelius E, Bergman B, Bendahl PO, et al
    Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  98. HAYASHI H, Mitsudomi T
    S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?
    Ann Oncol. 2017;28:2627-2629.
    PubMed     Text format    


    October 2017
  99. OTSUBO K, Seki N, Nakanishi Y, Okamoto I, et al
    Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    


  100. ULAHANNAN D, Khalifa J, Faivre-Finn C, Lee SM, et al
    Emerging treatment paradigms in brain metastasis in non-small cell lung cancer: an overview of the current landscape and challenges ahead.
    Ann Oncol. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  101. SORIA JC, Fulop A, Maciel C, Fischer JR, et al
    SELECT-2: a Phase II, double-blind, randomised, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment for patients with advanced or metastatic non-small cell lung cancer.
    Ann Oncol. 2017 Oct 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  102. MARTINEZ-MARTI A, Felip E, Matito J, Mereu E, et al
    Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Ann Oncol. 2017;28:2451-2457.
    PubMed     Text format     Abstract available


  103. CALVO E, Moreno V, Flynn M, Holgado E, et al
    Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Ann Oncol. 2017;28:2559-2566.
    PubMed     Text format     Abstract available


    September 2017
  104. NOKIHARA H, Lu S, Mok TSK, Nakagawa K, et al
    Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. WEBER S, Wolkewitz M, Schumacher M
    Analyzing the impact of Depth of Response on Survival in patients with metastatic non-small cell lung cancer.
    Ann Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format    


  106. ARGIRIS A, Lee JW, Stevenson J, Sulecki MG, et al
    Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3508).
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  108. KATAKAMI N, Felip E, Spigel DR, Kim JH, et al
    A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
    Ann Oncol. 2017;28:2241-2247.
    PubMed     Text format     Abstract available


  109. ITO M, Fujiwara S, Fujimoto D, Mori R, et al
    Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.
    Ann Oncol. 2017;28:2318-2319.
    PubMed     Text format    


  110. MANAPOV F, Eze C
    Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
    Ann Oncol. 2017;28:2319-2320.
    PubMed     Text format    


    August 2017
  111. SAAD ED, Buyse M
    Editorial on "Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy".
    Ann Oncol. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format    


  112. KOLLER M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, et al
    An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.
    Ann Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  113. MAENO K, Fukuda S, Oguri T, Niimi A, et al
    Nivolumab-induced asthma in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format    


  114. MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy.
    Ann Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  115. CURIONI-FONTECEDRO A, Ickenberg C, Franzen D, Rogler G, et al
    Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
    Ann Oncol. 2017;28:2040-2041.
    PubMed     Text format    


    July 2017
  116. LEDUC C, Merlio JP, Besse B, Blons H, et al
    Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
    Ann Oncol. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  117. HENTRICH M, Schipek-Voigt K, Jager H, Schulz S, et al
    Nivolumab in HIV-related non-small-cell lung cancer.
    Ann Oncol. 2017 Jul 6. doi: 10.1093.
    PubMed     Text format    



  118. Appendix 8: Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    Ann Oncol. 2017;28.
    PubMed     Text format    



  119. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    Ann Oncol. 2017;28.
    PubMed     Text format    


  120. POSTMUS PE, Kerr KM, Oudkerk M, Senan S, et al
    Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2017;28.
    PubMed     Text format    


  121. BOLAND JM, Mansfield AS, Roden AC
    Pulmonary sarcomatoid carcinoma-a new hope.
    Ann Oncol. 2017;28:1417-1418.
    PubMed     Text format    


  122. PECUCHET N, Vieira T, Rabbe N, Antoine M, et al
    Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.
    Ann Oncol. 2017;28:1597-1604.
    PubMed     Text format     Abstract available


  123. LESAFFRE E, Edelman MJ, Hanna NH, Park K, et al
    Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
    Ann Oncol. 2017;28:1419-1426.
    PubMed     Text format     Abstract available


    June 2017
  124. TOMITA Y, Sueta D, Kakiuchi Y, Saeki S, et al
    Acute Coronary Syndrome as a Possible Immune-Related Adverse Event in a Lung Cancer Patient Achieving a Complete Response to Anti-PD-1 Immune Checkpoint Antibody.
    Ann Oncol. 2017 Jun 23. doi: 10.1093.
    PubMed     Text format    


  125. LINDSAY CR, Faugeroux V, Michiels S, Pailler E, et al
    A Prospective Examination of Circulating Tumor Cell Profiles in Non-Small Cell Lung Cancer Molecular Subgroups.
    Ann Oncol. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  126. DEVARAKONDA S, Govindan R
    TRAC(ERx)-ing Lung Cancer Evolution.
    Ann Oncol. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format    


  127. SANMAMED MF, Perez-Gracia JL, Schalper KA, Fusco JP, et al
    Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients.
    Ann Oncol. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  128. DURUISSEAUX M, Mc Leer-Florin A, Moro-Sibilot D, Cadranel J, et al
    Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?
    Ann Oncol. 2017;28:1401.
    PubMed     Text format    


  129. KIM HR, Kang HN, Shim HS, Kim EY, et al
    Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    Ann Oncol. 2017;28:1250-1259.
    PubMed     Text format     Abstract available


    May 2017
  130. CHRISTOPOULOS P, Engel-Riedel W, Grohe C, Kropf-Sanchen C, et al
    Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
    Ann Oncol. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  131. CURROW D, Temel JS, Abernethy A, Milanowski J, et al
    ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia.
    Ann Oncol. 2017 May 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  132. GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.
    Ann Oncol. 2017;28:1084-1089.
    PubMed     Text format     Abstract available


  133. ZHANG L, Ye Y, Tu H, Hildebrandt MA, et al
    MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.
    Ann Oncol. 2017;28:1124-1129.
    PubMed     Text format     Abstract available


  134. BESSE B, Mazieres J, Ribassin-Majed L, Barlesi F, et al
    Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
    Ann Oncol. 2017;28:1078-1083.
    PubMed     Text format     Abstract available


    April 2017
  135. DHILLON HM, Bell ML, van der Ploeg HP, Turner JD, et al
    Impact of Physical Activity on Fatigue and Quality of Life in People with Advanced Lung Cancer: a Randomised Controlled Trial.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  136. HARATANI K, Hayashi H, Tanaka T, Kaneda H, et al
    Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  137. SEO S, Woo CG, Lee DH, Choi J, et al
    The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small cell lung cancer.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format    


  138. FERRONIKA P, van den Bos H, Taudt A, Spierings DCJ, et al
    Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small cell lung cancer patient.
    Ann Oncol. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format    


  139. ZHANG Y, Zhang L, Li R, Chang DW, et al
    Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.
    Ann Oncol. 2017 Apr 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  140. REMON J, Caramella C, Jovelet C, Lacroix L, et al
    Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
    Ann Oncol. 2017;28:784-790.
    PubMed     Text format     Abstract available


    March 2017
  141. KATAOKA Y, Ebi N, Fujimoto D, Hara S, et al
    Prior radiotherapy does not predict nivolumab response in non-small cell lung cancer: a retrospective cohort study.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Text format    


  142. KIM ST, Kim SY, Klempner SJ, Yoon J, et al
    Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
    Ann Oncol. 2017;28:547-554.
    PubMed     Text format     Abstract available


  143. CHANDRANI P, Prabhash K, Prasad R, Sethunath V, et al
    Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
    Ann Oncol. 2017;28:597-603.
    PubMed     Text format     Abstract available


    February 2017
  144. ZOU T, Awad MM
    More valuable than platinum: first-line pembrolizumab in advanced stage non-small cell lung cancer.
    Ann Oncol. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format    


  145. GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomised trial.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  146. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2017, with focus on lung cancer.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  147. PAZ-ARES L, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Ann Oncol. 2017;28:270-277.
    PubMed     Text format     Abstract available


  148. YOSHIOKA H, Katakami N, Okamoto H, Iwamoto Y, et al
    A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
    Ann Oncol. 2017;28:285-291.
    PubMed     Text format     Abstract available


  149. REMON J, Soria JC
    Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
    Ann Oncol. 2017;28:196-198.
    PubMed     Text format    


  150. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Text format     Abstract available


  151. YU HA, Sima C, Feldman D, Liu LL, et al
    Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
    Ann Oncol. 2017;28:278-284.
    PubMed     Text format     Abstract available


    January 2017
  152. KADARA H, Choi M, Zhang J, Parra ER, et al
    Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Ann Oncol. 2017;28:75-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: